Completed PHASE4 INTERVENTIONAL 2-arm NCT01306253

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere

Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2009/2010-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations

Sponsor: Crucell Holland BV

Conditions Influenza

Interventions Inflexal V

Updated 5 times since 2017 Last updated: Aug 29, 2013 Started: Jun 30, 2009 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01306253, this PHASE4 trial focuses on Influenza and remains completed. Sponsored by Crucell Holland BV, it has been updated 5 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Crucell Holland BV

Data source: Crucell Holland BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Allschwil, Switzerland